SION is a binary event stock tied to Phase 2a SION-719 proof-of-concept data expected summer 2026. The completion of enrollment de-risks the timeline but provides no efficacy signal. Traders should monitor for sweat chloride data as the primary efficacy readout, positive results could drive significant upside given the large CF market opportunity, while negative results would likely be devastating for the stock. The $289.9M cash runway into 2028 provides ample time for multiple catalysts.
SION drugs
SION drug pipeline →Price Chart
Executive Summary
Sionna Therapeutics reported Q1 2026 financial results with a net loss of $26.8M ($-0.60/share), wider than the $16.5M loss in Q1 2025, as R&D and G&A expenses increased to support pipeline advancement. The key catalysts are the completion of enrollment in the Phase 2a trial of SION-719 and the ongoing Phase 1 dual combination trial of SION-451, both on track for topline data in summer 2026. Cash position of $289.9M is expected to fund operations into 2028, but the lack of revenue and widening losses make this a neutral operational update with binary event risk tied to upcoming clinical readouts.
Key Financial Metrics
Key Facts
- Net loss of $26.8M for Q1 2026 vs $16.5M in Q1 2025, driven by increased R&D ($19.0M vs $13.7M) and G&A ($10.6M vs $6.0M) expenses
- Cash, cash equivalents, and marketable securities of $289.9M as of March 31, 2026, down from $310.3M at year-end 2025
- Enrollment completed in PreciSION CF Phase 2a proof-of-concept trial of SION-719; topline data expected summer 2026
- Phase 1 dual combination trial of SION-451 with SION-2222 and SION-109 also on track for summer 2026 topline data
- Encore data from prior NACFC presentations to be featured at ECFS conference June 3-6, 2026
- No revenue generated; company is a clinical-stage biopharmaceutical with no approved products
Financial Impact
Net loss increased $10.3M year-over-year to $26.8M; cash burn of $20.4M in Q1 2026
Risk Factors
- Phase 2a trial failure or underwhelming efficacy data would severely impair stock value
- Cash burn rate increasing as trials advance; no revenue to offset expenses
- Competition from Vertex Pharmaceuticals' established CFTR modulator therapies
- Dilution risk from future capital raises to fund ongoing trials and operations
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001628280-26-033870 |
| Document: sion-20260512.htm | 0001628280-26-033870 |
| Document: 0001628280-26-033870-index-headers.html | 0001628280-26-033870 |
| Document: 0001628280-26-033870-index.html | 0001628280-26-033870 |
| Document: 0001628280-26-033870.txt | 0001628280-26-033870 |
| 8-K Data (Synthetic) | 0001628280-26-033870 |
Track record
22 reports on SION
7 of 9 bullish or bearish reports moved the stock their way by T+5. Best: +89.29% at T+60 after the Jul 9, 2026 report. 9 of 9 went positive at some point.
Filters
- Nov 10, 20266d ago Press Release Neutral 5/10 Entry $3.70 Now $3.12 −15.68% settles Nov 17
- Nov 9, 20267d ago SC 13G Neutral 3/10 Entry $3.57 to $3.12 Now $3.12 −12.61% ▼ −12.61% −10.91% vs SPY
- Nov 3, 202613d ago Institutional Cluster Neutral 2/10 Entry $3.65 to $3.70 Now $3.12 −14.52% ▲ +1.37% +1.96% vs SPY
- Sep 22, 20267w ago Institutional Cluster Mixed 3/10 Entry $6.02 to $5.15 Now $3.12 −48.17% ▼ −14.45% −13.26% vs SPY
- Sep 21, 20268w ago SC 13D/A Bearish 7/10 Entry $6.02 to $5.15 Now $3.12 +48.17% ▲ +14.45% +13.26% vs SPY
- Sep 17, 20268w ago 144 Bearish 5/10 Entry $5.96 to $5.23 Now $3.12 +47.65% ▲ +12.25% +13.52% vs SPY
- Aug 10, 202614w ago 8-K Bearish 7/10 Entry $4.50 to $5.91 Now $3.12 +30.67% ▼ −31.33% −31.38% vs SPY
- Aug 6, 202614w ago 8-K Neutral 4/10 Entry $49.61 to $6.54 Now $3.12 −93.71% ▼ −86.82% −88.03% vs SPY
- Jul 9, 202618w ago Insider Cluster Neutral 4/10 Entry $45.29 to $45.29 Now $3.12 −93.11% · 0.00% +0.56% vs SPY
- Jul 9, 202618w ago Insider Cluster Bearish 5/10 Entry $45.29 to $45.29 Now $3.12 +93.11% · 0.00% −0.56% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers